Organisation paid for research Program year 2025 Source: CMS Open Payments

Clintex Research Group Inc

Neither a doctor nor a teaching hospital

Research payments

$1,600,628

78 payments

Through program year 2025, Clintex Research Group Inc is reported as receiving $1,600,628 in research payments, across 78 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $830,959 30
2024 Research $595,094 12
2023 Research $3,779 3
2021 Research $61,517 5
2020 Research $59,791 11
2019 Research $49,489 17

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $1,459,792 52 payments
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $98,433 4 payments
  3. LivaNova USA, Inc. $39,521 16 payments
  4. GlaxoSmithKline, LLC. $2,690 2 payments
  5. Pfizer Inc. $192 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma $1,192,090 31 payments
  2. An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 $221,095 10 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $52,638 2 payments
  4. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression $37,492 14 payments
  5. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function $33,981 9 payments
  6. Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD $32,927 1 payment
  7. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post?Traumatic Stress Disorder $12,868 1 payment
  8. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi $8,544 1 payment
  9. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi $4,081 1 payment
  10. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) $2,029 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record